Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Indication

Heart Failure with Preserved Ejection Fraction

61 clinical trials

59 products

6 drugs

Product
CDR132L
Clinical trial
Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Safety and Efficacy Study of CDR132L on Reverse Cardiac Remodeling in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction and Cardiac Hypertrophy
Status: Not yet recruiting, Estimated PCD: 2025-09-01
Product
Placebo
Clinical trial
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Assess the Safety and Effectiveness of Tovinontrine in Patients With Chronic Heart Failure With Preserved Ejection Fraction
Status: Recruiting, Estimated PCD: 2025-10-01
Product
Tovinontrine
Clinical trial
A Randomised, Double-blind, Placebo-controlled, Multi-center Sequential Phase 2b and Phase 3 Study to Evaluate the Efficacy and Safety of AZD4831 Administered for Up to 48 Weeks in Participants With Heart Failure With Left Ventricular Ejection Fraction > 40%
Status: Completed, Estimated PCD: 2024-03-27
Product
AZD4831
Product
HU6
Clinical trial
Exploratory Phase 2A, Double-blind, Placebo-Controlled, Dose Escalation Study to Determine the Safety, Tolerability, PD, and PK of HU6 for the Treatment of Subjects With Obese Heart Failure With Preserved Ejection Fraction (HFpEF)
Status: Active (not recruiting), Estimated PCD: 2024-05-30
Product
Tirzepatide
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Comparing the Efficacy and Safety of Tirzepatide Versus Placebo in Patients With Heart Failure With Preserved Ejection Fraction and Obesity (SUMMIT)
Status: Active (not recruiting), Estimated PCD: 2024-06-01
Clinical trial
A Multicenter, Randomized, Double-blind, Placebo-parallel-controlled, Phase II Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Obese Subjects With Heart Failure With Preserved Ejection Fraction
Status: Not yet recruiting, Estimated PCD: 2025-09-01
Product
HRS9531
Product
LY3540378
Clinical trial
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of LY3540378 in Adults With Worsening Chronic Heart Failure With Preserved Ejection Fraction (HFpEF)
Status: Recruiting, Estimated PCD: 2025-11-01
Product
sacubitril/valsartan
Clinical trial
A Multicenter, Randomized, Double-blind, Double-dummy, Parallel Group, Active Controlled Study to Evaluate the Effect of Sacubitril/Valsartan (LCZ696) Versus Valsartan on Changes in NT-proBNP, Safety, and Tolerability in HFpEF Patients With a WHF Event (HFpEF Decompensation) Who Have Been Stabilized and Initiated at the Time of or Within 30 Days Post-decompensation (PARAGLIDE-HF)
Status: Completed, Estimated PCD: 2022-12-14
Product
valsartan
Clinical trial
A Phase 2, Multicentre, Double-Blind, Placebo and Active Control Efficacy and Safety Study to Evaluate Verinurad Combined With Allopurinol in Heart Failure With Preserved Ejection Fraction
Status: Completed, Estimated PCD: 2022-04-29
Product
Placebo for verinurad
Product
Verinurad
Product
Allopurinol
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, Single-Ascending Dose Study to Assess the Safety and Tolerability of JK07 in Subjects With Heart Failure With Preserved Ejection Fraction (HFpEF)
Status: Withdrawn, Estimated PCD: 2023-05-26
Product
Matching Placebo
Product
Macitentan
Clinical trial
A Multi-center, Double-blind, Placebo-controlled Phase 2b Study to Evaluate the Efficacy and Safety of Macitentan in Subjects With Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease
Status: Completed, Estimated PCD: 2021-03-12
Clinical trial
A Phase 1b, Pilot Trial Evaluating the Safety and Pharmacodynamic Effects of SRD-001 (AAV1-SERCA2a) in Subjects With Heart Failure With Preserved Ejection Fraction
Status: Recruiting, Estimated PCD: 2025-08-01
Product
AAV1/SERCA2a
Clinical trial
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study Evaluating the Safety and Efficacy of Different Doses of IW-1973 Over 12 Weeks in Patients With Heart Failure With Preserved Ejection Fraction
Status: Completed, Estimated PCD: 2019-08-19
Product
IW-1973
Product
JK07
Clinical trial
Selective PDE9 Inhibition With IMR-687 in Adults With Heart Failure With Preserved Ejection Fraction: a Safety and Efficacy Phase 2 Randomized Clinical Study (SP9In-HFpEF)
Status: Withdrawn, Estimated PCD: 2023-09-01
Product
IMR-687
Product
mavacamten
Clinical trial
An International, Double-blind, Randomised, Placebo-Controlled Phase III Study to Evaluate the Effect of Dapagliflozin on Reducing CV Death or Worsening Heart Failure in Patients With Heart Failure With Preserved Ejection Fraction (HFpEF)
Status: Completed, Estimated PCD: 2022-03-27
Product
Dapagliflozin
Clinical trial
An Exploratory, Open-label, Proof-of-concept, Phase 2a Study of Mavacamten (MYK-461) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Chronic Elevation of Cardiac Biomarkers
Status: Active (not recruiting), Estimated PCD: 2024-04-15
Product
CRD-740
Clinical trial
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Assess the Effectiveness of CRD-740 in Subjects With Chronic Heart Failure (CARDINAL-HF)
Status: Terminated, Estimated PCD: 2023-05-02
Clinical trial
Efficacy and Safety of Qishenyiqi Dripping Pills for Treating Chronic Heart Failure With Preserved Ejection Fraction: a Randomized, Double-blind, Basic-treatment-loading, Placebo-controlled, Multicenter Phase Ⅱ Clinical Trial
Status: Recruiting, Estimated PCD: 2024-07-01
Product
Qishen Yiqi dripping pills
Product
Qishen Yiqi
Clinical trial
Reversing Microvascular Dysfunction in Heart Failure With Ejection Fraction > 40% Using Colchicine (The COL-Micro-HF Study)
Status: Not yet recruiting, Estimated PCD: 2025-10-01
Product
Colchicine
Clinical trial
Cilostazol for HFpEF (Heart Failure With a Preserved Ejection Fraction)
Status: Completed, Estimated PCD: 2022-06-01
Product
Cilostazol
Clinical trial
Impact of Empagliflozin on Functional Capacity in Heart Failure With Preserved Ejection Fraction
Status: Completed, Estimated PCD: 2023-09-20
Product
Empagliflozin
Clinical trial
Evaluation of the Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction (CAMEO-SEMA) A Phase II, Prospective, Double-Blind Randomized Trial
Status: Recruiting, Estimated PCD: 2026-08-01
Product
Semaglutide
Clinical trial
A Double-Blind, Randomized, Placebo-Controlled Study of Levosimendan in Pulmonary Hypertension Patients With Heart Failure With Preserved Left Ventricular Ejection Fraction (PH-HFpEF)
Status: Completed, Estimated PCD: 2020-04-07
Product
Levosimendan
Clinical trial
Enhanced Diuresis and Natriuresis in Acute Decompensated Heart Failure Patients Treated With SGLT-2 Inhibitor and High-Dose Furosemide Plus Small-Volume Hypertonic Saline Solution: A Clinical Trial
Status: Not yet recruiting, Estimated PCD: 2026-01-31
Product
Hypertonic Saline Solution
Product
Furosemide
Clinical trial
The Effect of Addition of Metformin to SGLT2 In Diabetic Patients With Heart Failure With Preserved Ejection Fraction
Status: Not yet recruiting, Estimated PCD: 2024-11-01
Drug
Metformin
Clinical trial
Slow-release CArvedilol in Patients With REduced Strain and Preserved Ejection Fraction Heart Failure (CARE-preserved HF): A Prospective Randomized, Double-Blinded, Multicenter Study
Status: Recruiting, Estimated PCD: 2024-08-30
Product
Carvedilol
Clinical trial
The Effect of Empagliflozin on Peripheral Microvascular Dysfunction in Heart Failure With
Status: Recruiting, Estimated PCD: 2024-08-13
Product
Empaglifozin
Clinical trial
The Safety and Efficacy of Empagliflozin in Patients With End-stage Renal Disease and Heart Failure With Preserved Ejection Fraction - a Randomized Controlled Trial
Status: Not yet recruiting, Estimated PCD: 2027-12-31
Clinical trial
Sodium-dependent Glucose Transporters 2 Inhibitor in Nonobstructive Hypertrophic Cardiomyoapthy Patients With Heart Failure With Preserved Ejection Fraction: a Prospective, Multi-center,Open-lable,Randomized Controlled Trial
Status: Recruiting, Estimated PCD: 2024-08-01
Clinical trial
Effect of Dapagliflozin on Metabolomics and Cardiac Mechanics in Chronic Kidney Disease
Status: Recruiting, Estimated PCD: 2026-03-01
Clinical trial
Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure With Preserved Ejection Fraction, SPIRRIT-HFPEF
Status: Recruiting, Estimated PCD: 2026-12-01
Product
Spironolactone
Clinical trial
Sodium-glucose Cotransporter 2 Inhibitor, Aldosterone Antagonist, or Both for Heart Failure With Preserved Ejection Fraction: a Two-centre Randomised Three-treatment Three-period Crossover Trial
Status: Recruiting, Estimated PCD: 2024-09-15
Drug
Dapagliflozin
Product
Spironolactone + Dapagliflozin
Clinical trial
N-of-1 Trials for Deprescribing Beta-blockers in HFpEF
Status: Completed, Estimated PCD: 2023-04-28
Drug
Beta blockers
Clinical trial
Sacubitril-Valsartan in Heart Failure With Preserved Ejection Fraction and Secondary Mitral Valve Regurgitation
Status: Recruiting, Estimated PCD: 2025-09-01
Product
Sacubitril-valsartan
Product
Standard of care
Clinical trial
Ending Subclinical Heart Failure Using an Aldosterone and Natriuretic Peptide Targeted Treatment in HIV--The ENCHANTMENT HIV Study
Status: Recruiting, Estimated PCD: 2024-06-30
Product
Sacubitril-Valsartan
Clinical trial
Sodium-glucose Cotransporter-2 (SGLT2) Inhibitors, Ketones, and Cardiovascular Benefit Research Plan
Status: Recruiting, Estimated PCD: 2026-11-30
Drug
Varlilumab
Clinical trial
Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Effects of Enavogliflozin on Outcomes in Patients With Functional Tricuspid Regurgitation and Heart Failure With Preserved Left Ventricular Ejection Fraction
Status: Recruiting, Estimated PCD: 2026-04-01
Product
Enavogliflozin
Clinical trial
A Double-blind,Randomized, Placebo-controlled Study to Assess Exercise Tolerance After Iron Repletion With Ferric Derisomaltose (Monoferric®) IV Compared to Placebo in Heart Failure With Preserved Ejection Fraction and With Iron Deficiency.
Status: Recruiting, Estimated PCD: 2025-02-28
Product
Ferric Derisomaltose
Clinical trial
BLOCKade of Calcium Channels and Beta Adrenergic Receptors for the Treatment of Hypertension in Heart Failure With Preserved Ejection Fraction (BLOCK HFpEF) Trial
Status: Recruiting, Estimated PCD: 2024-10-01
Product
Amlodipine
Product
Metoprolol
Clinical trial
Evaluation of the Cardiac and Metabolic Effects of Dapagliflozin in Heart Failure With Preserved Ejection Fraction (CAMEO-DAPA): A Phase II, Prospective, Double-Blind Study
Status: Completed, Estimated PCD: 2022-11-17
Clinical trial
Metformin for Older Patients With Heart Failure With Preserved Ejection Fraction
Status: Recruiting, Estimated PCD: 2025-03-01
Clinical trial
The Effects of Ferric Derisomaltose Administered Before Hospital Discharge in Stabilised Patients With Acute Heart Failure and Iron Deficiency on Exercise Capacity and Quality of Life: a Randomised, Parallel-group, Double-blind, Placebo Controlled Trial (COREVIVE-HFpEF)
Status: Recruiting, Estimated PCD: 2024-08-01
Product
Ferric derisomaltose
Clinical trial
Exploring Clinical Characteristics and Predictors of Adverse Outcomes in Patients Diagnosed With Heart Failure With Preserve Ejection Fraction (HFpEF)
Status: Completed, Estimated PCD: 2023-07-20
Product
Comparison Study
Clinical trial
N-of-1 Trials for Deprescribing Beta-blockers in HFpEF
Status: Completed, Estimated PCD: 2022-04-28
Clinical trial
SOTA-P-CARDIA Trial: A Randomized Trial of Sotagliflozin in HFpEF Patients Without Diabetes
Status: Recruiting, Estimated PCD: 2025-11-01
Product
Sotagliflozin
Clinical trial
Developing Oral LT3 Therapy For Heart Failure With Preserved Ejection Fraction
Status: Completed, Estimated PCD: 2023-10-31
Product
Liothyronine
Clinical trial
Pioglitazone, Lipotoxicity, and Heart Failure With Preserved Ejection Fraction (HFpEF)
Status: Recruiting, Estimated PCD: 2028-04-01
Product
Pioglitazone
Clinical trial
The COLchicine HEART Failure PRESERVED Trial (COLHEART-PRESERVED)
Status: Recruiting, Estimated PCD: 2026-06-01
Clinical trial
Evaluation of GeranylGeranylAcetone in Heart Failure With Preserved Ejection Fraction
Status: , Estimated PCD: 2025-04-26
Product
Geranylgeranylacetone
Clinical trial
Polydiuretic Therapy for Heart Failure With Preserved Ejection Fraction: A Pilot Trial
Status: Recruiting, Estimated PCD: 2023-12-31
Product
Low dose combination polydiuretic therapy
Clinical trial
Circulating Biomarkers of Fibrosis and Cardiovascular Disease in Patients With Heart Failure With Preserved Ejection Fraction - Analysis of Samples Collected as Part of the PIROUETTE Trial
Status: Completed, Estimated PCD: 2019-11-29
Drug
Pirfenidone
Clinical trial
A Randomized, Double-blind, Placebo-controlled Study on the Treatment of Heart Failure With Preserved Ejection Fraction With Qishen Granules Based on Cardiopulmonary Exercise Test
Status: Recruiting, Estimated PCD: 2024-12-31
Product
Qishen Granules
Clinical trial
A PILOT TRIAL OF CELL THERAPY IN HEART FAILURE WITH PRESERVED EJECTION FRACTION
Status: Completed, Estimated PCD: 2022-01-01
Product
Cell Therapy
Clinical trial
Matching Perfusion and Metabolic Activity in HFpEF
Status: Recruiting, Estimated PCD: 2026-01-31
Product
Potassium Nitrate
Product
Potassium Nitrate + Propionyl-L-Carnitine + Nicotinamide Riboside
Clinical trial
Allopurinol Improves Diastolic Function in African Americans With Resistant Hypertension
Status: Recruiting, Estimated PCD: 2025-03-26
Drug
Allopurinol
Clinical trial
Administration of the SGLT-2 Inhibitor Dapagliflozin in the Patients With Amyloid Cardiomyopathy: a Pilot Study
Status: Recruiting, Estimated PCD: 2025-01-01
Clinical trial
A Preliminary Study for the Intervention of an N-of-1 Protocol For Medication Optimization
Status: Recruiting, Estimated PCD: 2026-07-01
Product
Beta blocker
Clinical trial
Empagliflozin on the Function of Left Atrium in Heart Failure With Mildly Reduced or Preserved Ejection Fraction
Status: , Estimated PCD: 2024-10-01
Clinical trial
Enhancing the Natriuretic Peptide System in HFpEF: A Randomized Double-Blind Placebo-Controlled Triple Crossover Study
Status: , Estimated PCD: 2027-04-01
Product
MANP
Product
Sacubitril/Valsartan
Product
Injection Placebo
Clinical trial
SGLT2i and KNO3 in HFpEF - The SAK HFpEF Trial
Status: Recruiting, Estimated PCD: 2026-03-01
Product
Empagliflozin + Potassium Chloride
Product
Potassium Chloride + Placebo
Clinical trial
A Phase 2 Randomized, Double-blind, Placebo-controlled Study to Assess the Safety and Efficacy of JK07 in Adults With Chronic Heart Failure (RENEU-HF)
Status: Recruiting, Estimated PCD: 2025-12-31